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reaches significance in the RECOVER study (p  0.021); however,
the 2 more stringent surrogate definitions that were used in the
NEPHRIC study (0.5 mg/dl; 1.0 mg/dl increase over baseline)
both did not reach significance. Thus, in terms of statistical
significance the RECOVER study does not confirm the NEPHRIC
study (i.e., no beneficial effect of iso-osmolar CM over LOCM).
Regarding outcome end points, the RECOVER study actually
shows no, let alone significant, differences between the agents.
Acute renal failure requiring dialysis occurred only once in both the
iodixanol and the ioxaglate groups. One can argue that the more
stringent/relevant the end points the less or even nonexistent are
the differences between the 2 groups in the RECOVER study.
Still, the RECOVER study results seem to contradict the findings
of our registry study, as the outcome end points showed no
differences between the agents. However, the size of the RE-
COVER study with 275 patients is much too small to detect
differences between the rarely occurring outcome events.
Our registry study, conversely, included over 57,000 patients, a
size adequate to detect such small differences in an important end
point as acute renal failure. Finally, we notice a discrepancy
between the patient numbers in the groups published in a previous
abstract on the RECOVER study (5) where the iodixanol group
had some 20 patients more and the ioxaglate group had some 20
patients less, which may interfere with the investigators’ analysis.
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Reply
We thank Dr. Deray and Dr. Persson and colleagues for giving us an
opportunity to clarify the reason behind sample size discrepancy
between published RECOVER (Renal Toxicity Evaluation and
Comparison Between Visipaque [Iodixanol] andHexabrix [Ioxaglate]
in Patients With Renal Insufficiency Undergoing Coronary Angiog-
raphy) and abstracts presented in scientific meetings (1–3) and to
explain some issues.
Persson et al. (4) reported the finding of iodixanol inferiority
contrary to that of the RECOVER study. However, the study by
Persson et al. (4) was a retrospective study that had many compound-
ing factors influencing results. The researchers did not present the
basal serum creatinine and contrast dose of all patients, and the
baseline characteristics of study groups were significantly different.
Most importantly, previous renal failure, prior dialysis, ST-segment
elevation myocardial infarction (STEMI), and unstable coronary
diseases were more frequent in the iodixanol group, all of which were
very critical determinants in developing contrast-induced nephropathy
(CIN) and affecting clinical outcomes. We do not agree with Persson
et al. (4) because of these critical limitations.
We showed a trend of lower CIN incidence in iodixanol by the
more stringent criteria (serum creatinine increase 0.5 mg/dl) as
in the NEPHRIC (Nephrotoxicity in High-Risk Patients Study of
Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media) (5)
despite failure to reach statistical significance (3.6% vs. 8.9%, p 
0.067). We disagree with the view of Dr. Persson and colleagues
that iso-osmolar contrast media had no beneficial effect over
low-osmolar contrast media owing to a p value of 0.067. Other
investigations support the superiority of iodixanol, such as Chalmers’
study, the NEPHRIC study, and recent meta-analyses (6,7).
Regarding the different sample size, only preliminary data of the
RECOVER study were shown in scientific meetings, and registry
data collected during the same period that the RECOVER study was
conducted were erroneously incorporated into randomization data.
Therefore, the iodixanol group was asymmetrically larger, and total
patient population was higher in abstracts of scientific meetings.
We agree withDr.Deray’s comment that it would be better to present
both intention-to-treat and per-protocol analyses. However, many inves-
tigators presented their data only by per-protocol analysis (8). Moreover,
both analyses made no differences in the RECOVER trial.
We already addressed the issues regarding different age and
similar clinical outcomes of our study. Some studies reported age
over 75 as the risk factor of CIN (9). In the RECOVER study, the
mean age of both groups was under 75 years, and the proportion
of patients over 75 was 18% in the iodixanol group and 22% in the
ioxaglate group, with no difference (p 0.451). We do not believe
that the age difference influenced our results.
Finally, all patients in the RECOVER study received adequate
periprocedural hydration, and the body weight was similar in the 2
groups, as depicted in the study. Although the exact level of hydration
was only available in some patients, volume status was evaluated by
both physical examination and laboratory test in all patients. There-
after, dehydrated and acute renal-failure patients were excluded.
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Is Thrombus Aspiration
the Appropriate “Remedy”?
The recently published substudy of the REMEDIA (Random-
ized Evaluation of the Effect of Mechanical Reduction of Distal
Embolization by Thrombus-Aspiration in Primary and Rescue
Angioplasty) trial by Galiuto et al. (1) raises a number of
important issues regarding routine use of thrombectomy devices
in the setting of acute ST-segment elevation myocardial infarc-
tion. To date, results from recently published larger randomized
studies of distal protection have shown a neutral effect (2–4).
Furthermore, relevant results were obtained in 2 of these studies
regarding an associated increase in infarct size (3,4).
The original REMEDIA trial (5), however, showed im-
proved myocardial blush grade and ST-segment resolution in
the thrombectomy arm. The Galiuto et al. (1) substudy of this
trial further evaluates potential mechanisms behind this finding.
In this substudy, patients were evaluated with myocardial
contrast echocardiography (MCE) at 24 h, 1 week, and 6
months, with consistent improvements seen over these time
periods, not only in microvascular but also myocardial function.
These results, though promising, should be viewed in light of
not only the previously published neutral studies, but also the
PROMISE (Protection Devices in PCI Treatment of Myocar-
dial Infarction for Salvage of Endangered Myocardium)
study (6).
Utilizing Doppler Flo-wire and cardiac magnetic resonance
imaging evaluation, the PROMISE study had neutral findings
regarding microvascular function and infarct size. Differences
between the Galiuto et al. (1) and PROMISE (6) studies are
important to note, particularly when evaluating their different
conclusions. It is possible that the microvascular circulation
following primary angioplasty remains dysfunctional in the
short term but begins to normalize over 12 to 24 h. This would
explain both the immediate postangioplasty neutral result of the
Doppler Flo-wire study and positive results of the MCE
evaluation over time. Furthermore, it is possible that initial
passage of a distal protection device (i.e., filter wire or distal
balloon occlusion device) may result in distal embolization, a
process that might be reduced with isolated thrombectomy
catheter use.
However, the major concern relates to the Galiuto et al. (1)
study being potentially underpowered. As no power calculations
were provided in this trial, we are unable to assess whether 50
patients is appropriate; of note, the negative PROMISE study
randomized 4 times more subjects.
Although the findings of the small Galiuto et al. (1) study are
promising, the weight of evidence of larger randomized trials
supports a neutral effect of distal protection on both microvascular
and myocardial function. Further evaluation of such devices is
imperative, particularly in selected cases such as those with large
angiographic thrombus burden.
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